AbbVie (ABBV) shares snapped eight consecutive sessions of losses as the stock closed up XYZ% at $XYZ. The North ...
Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...
Zacks.com on MSN22h
AbbVie's Ovarian Cancer Drug Elahere Gets Approval in EuropeThe EC has approved Elahere for treating adult patients with folate receptor-alpha (FRα) positive, platinum-resistant and ...
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: ...
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
AbbVie has rewarded shareholders again with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...
Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
AbbVie receives European marketing approval for Elahere for the treatment of platinum-resistant ovarian cancer: North Chicago, Illinois Tuesday, November 19, 2024, 10:00 Hrs [IST] ...
On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $164.99 which represents a decrease of $-4.64 or -2.74% from the prior close of $169.63. The stock opened at $169.63 and touched a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback